BIEL × Viant × VLMS × Strategic Marketing Partner
Strategic Equity Meets Scalable Healthcare Branding—and Global Market Reentry
Just as Viant scales production and VLMS drives distribution, a marketing firm can take an open-market equity stake in BIEL to become a compounding stakeholder—earning returns from rising PPS while fueling brand virality, consumer adoption, and shelf-space expansion.
This alliance doesn’t just drive growth—it solves problems. Together, these partners fill the KT Tape void and unlock a path back into the EU/UK market, where ActiPatch® was previously withdrawn due to CE mark cost increases.
Each Partner’s Strategic Role
Viant Medical Produces FDA-cleared wearables at scale and brings global manufacturing infrastructure. With European operations and CE-certified relationships, Viant could:
Connect BIEL to EU-based OEMs for CE reentry
Co-invest in MDR recertification if strategic upside justifies it
VLMS Healthcare Drives commercialization and reimbursement. VLMS could:
Activate EU/UK distribution via wellness channels
Leverage its network to identify notified bodies or OEMs
Support relabeling strategy for non-medical positioning
Marketing Company Replaces KT Tape’s brand presence with influencer campaigns, retail activation, and e-commerce velocity. They could:
Rebrand ActiPatch® for wellness use to bypass CE constraints
Launch EU-facing campaigns focused on vitality, mobility, and drug-free recovery
Monetize adoption through affiliate and retail partnerships
BIEL The product innovator and equity platform—now backed by partners who solve regulatory hurdles and scale globally.
Filling the KT Tape Void
With KT Tape’s exit, BIEL’s alliance steps in with:
Viant’s manufacturing power
VLMS’s distribution velocity
Marketing firm’s brand amplification
Together, they transform ActiPatch® into a mainstream wellness powerhouse, ready for retail shelves, influencer channels, and international expansion.
Milestone-Based PPS Growth
$400K quarterly revenue → PPS to $0.01
$10M profit → PPS to $0.04
Full U.S. insurance reimbursement → PPS to $0.25–$0.40
Veterinary + Global rollouts → Compounded equity upside
Unified Flywheel for PPS Acceleration
Viant builds → Product supply scales VLMS bills → Distribution & revenue unlock Marketing firm amplifies → Brand awareness and consumer adoption explode BIEL executes milestones → PPS rises, equity compounding begins All partners gain → Stake values multiply without dilution
Strategic Equity Meets Scalable Healthcare Branding—and Global Market Reentry
Just as Viant scales production and VLMS drives distribution, a marketing firm can take an open-market equity stake in BIEL to become a compounding stakeholder—earning returns from rising PPS while fueling brand virality, consumer adoption, and shelf-space expansion.
This alliance doesn’t just drive growth—it solves problems. Together, these partners fill the KT Tape void and unlock a path back into the EU/UK market, where ActiPatch® was previously withdrawn due to CE mark cost increases.
Each Partner’s Strategic Role
Viant Medical Produces FDA-cleared wearables at scale and brings global manufacturing infrastructure. With European operations and CE-certified relationships, Viant could:
Connect BIEL to EU-based OEMs for CE reentry
Co-invest in MDR recertification if strategic upside justifies it
VLMS Healthcare Drives commercialization and reimbursement. VLMS could:
Activate EU/UK distribution via wellness channels
Leverage its network to identify notified bodies or OEMs
Support relabeling strategy for non-medical positioning
Marketing Company Replaces KT Tape’s brand presence with influencer campaigns, retail activation, and e-commerce velocity. They could:
Rebrand ActiPatch® for wellness use to bypass CE constraints
Launch EU-facing campaigns focused on vitality, mobility, and drug-free recovery
Monetize adoption through affiliate and retail partnerships
BIEL The product innovator and equity platform—now backed by partners who solve regulatory hurdles and scale globally.
Filling the KT Tape Void
With KT Tape’s exit, BIEL’s alliance steps in with:
Viant’s manufacturing power
VLMS’s distribution velocity
Marketing firm’s brand amplification
Together, they transform ActiPatch® into a mainstream wellness powerhouse, ready for retail shelves, influencer channels, and international expansion.
Milestone-Based PPS Growth
$400K quarterly revenue → PPS to $0.01
$10M profit → PPS to $0.04
Full U.S. insurance reimbursement → PPS to $0.25–$0.40
Veterinary + Global rollouts → Compounded equity upside
Unified Flywheel for PPS Acceleration
Viant builds → Product supply scales VLMS bills → Distribution & revenue unlock Marketing firm amplifies → Brand awareness and consumer adoption explode BIEL executes milestones → PPS rises, equity compounding begins All partners gain → Stake values multiply without dilution
